These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 31274738)
1. Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy. Wuarin R; Kakkassery V; Consigli A; Roquelaure D; Papanastasiou A; Schutz JS; Thumann G; Chronopoulos A Optom Vis Sci; 2019 Jul; 96(7):500-506. PubMed ID: 31274738 [TBL] [Abstract][Full Text] [Related]
2. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy? Hwang H; Kim JY; Kim KT; Chae JB; Kim DY Retina; 2020 Sep; 40(9):1724-1733. PubMed ID: 31584559 [TBL] [Abstract][Full Text] [Related]
3. Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy. Kwak JH; Hong SW; Ra H; Kim EC; Kang NY; Baek J Korean J Ophthalmol; 2019 Dec; 33(6):493-499. PubMed ID: 31833245 [TBL] [Abstract][Full Text] [Related]
4. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183 [TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F Retina; 2013; 33(10):2096-102. PubMed ID: 23719402 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380 [TBL] [Abstract][Full Text] [Related]
8. Retro-mode Imaging for retinal pigment epithelium alterations in central serous chorioretinopathy. Shin YU; Lee BR Am J Ophthalmol; 2012 Jul; 154(1):155-163.e4. PubMed ID: 22503695 [TBL] [Abstract][Full Text] [Related]
9. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy. Yasui A; Yamamoto M; Hirayama K; Shiraki K; Theisen-Kunde D; Brinkmann R; Miura Y; Kohno T Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):243-254. PubMed ID: 27497611 [TBL] [Abstract][Full Text] [Related]
10. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy. Liew G; Ho IV; Ong S; Gopinath B; Mitchell P Transl Vis Sci Technol; 2020 Dec; 9(13):6. PubMed ID: 33344050 [TBL] [Abstract][Full Text] [Related]
13. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Pitcher JD; Witkin AJ; DeCroos FC; Ho AC Br J Ophthalmol; 2015 Jun; 99(6):848-52. PubMed ID: 25595177 [TBL] [Abstract][Full Text] [Related]
14. Subretinal hyperreflective material in central serous chorioretinopathy. Sahoo NK; Govindhari V; Bedi R; Goud A; Singh R; Wu L; Chhablani J Indian J Ophthalmol; 2020 Jan; 68(1):126-129. PubMed ID: 31856489 [TBL] [Abstract][Full Text] [Related]
15. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785 [TBL] [Abstract][Full Text] [Related]
16. BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AS A PREDICTOR OF VISUAL OUTCOME AND RECURRENCE FOR CENTRAL SEROUS CHORIORETINOPATHY. Lee H; Lee J; Chung H; Kim HC Retina; 2016 Jul; 36(7):1372-80. PubMed ID: 26702841 [TBL] [Abstract][Full Text] [Related]
17. Macular ganglion cell complex thickness in acute and chronic central serous chorioretinopathy. Demirok G; Kocamaz F; Topalak Y; Altay Y; Sengun A Int Ophthalmol; 2017 Apr; 37(2):409-416. PubMed ID: 27324370 [TBL] [Abstract][Full Text] [Related]
18. Central Serous Chorioretinopathy: Morphological and Functional Outcome after Subthreshold Thermal Laser Coagulation with a Frequency-Doubled Nd:YAG Continuous-Wave Laser. Enders C; Lang GE; Mayer B; Werner JU Ophthalmologica; 2022; 245(1):59-68. PubMed ID: 34517369 [TBL] [Abstract][Full Text] [Related]
19. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy. Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972 [TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]